{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:06:01Z","timestamp":1787785561849,"version":"build-2784847793"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100005795","name":"Chang Gung Memorial Hospital, Linkou","doi-asserted-by":"crossref","award":["CMRPG8E1221"],"award-info":[{"award-number":["CMRPG8E1221"]}],"id":[{"id":"10.13039\/501100005795","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13075-018-1515-1","type":"journal-article","created":{"date-parts":[[2018,1,30]],"date-time":"2018-01-30T07:33:52Z","timestamp":1517297632000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Anti-CCP-positive patients with RA have a higher 10-year probability of fracture evaluated by FRAX\u00ae: a registry study of RA with osteoporosis\/fracture"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8943-5056","authenticated-orcid":false,"given":"Tien-Tsai","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan-Fu","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Mei","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin-Chou","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben Yu-Jih","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Chan","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Yuan","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Feng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Hua","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Ming","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,30]]},"reference":[{"key":"1515_CR1","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.1002\/1529-0131(200012)43:12<2776::AID-ANR18>3.0.CO;2-N","volume":"43","author":"G Haugeberg","year":"2000","unstructured":"Haugeberg G, Uhlig T, Falch JA, Halse JI, Kvien TK. Reduced bone mineral density in male rheumatoid arthritis patients: frequencies and associations with demographic and disease variables in ninety-four patients in the Oslo County Rheumatoid Arthritis Register. Arthritis Rheum. 2000;43:2776\u201384.","journal-title":"Arthritis Rheum"},{"key":"1515_CR2","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1136\/ard.60.5.521","volume":"60","author":"TM Huusko","year":"2001","unstructured":"Huusko TM, Korpela M, Karppi P, Avikainen V, Kautiainen H, Sulkava R. Threefold increased risk of hip fractures with rheumatoid arthritis in central Finland. Ann Rheum Dis. 2001;60:521\u20132.","journal-title":"Ann Rheum Dis"},{"key":"1515_CR3","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1186\/s12891-015-0733-9","volume":"16","author":"ML Rentero","year":"2015","unstructured":"Rentero ML, Amigo E, Chozas N, Fern\u00e1ndez Prada M, Silva-Fern\u00e1ndez L, Abad Hernandez MA, et al. Prevalence of fractures in women with rheumatoid arthritis and\/or systemic lupus erythematosus on chronic glucocorticoid therapy. BMC Musculoskelet Disord. 2015;16:300.","journal-title":"BMC Musculoskelet Disord"},{"key":"1515_CR4","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1136\/ard.2008.106484","volume":"68","author":"G Haugeberg","year":"2009","unstructured":"Haugeberg G, Conaghan PG, Quinn M, Emery P. Bone loss in patients with active early rheumatoid arthritis: infliximab and methotrexate compared with methotrexate treatment alone. Explorative analysis from a 12-month randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2009;68:1898\u2013901.","journal-title":"Ann Rheum Dis"},{"key":"1515_CR5","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/nyas.12446","volume":"1318","author":"KG Saag","year":"2014","unstructured":"Saag KG. Bone safety of low-dose glucocorticoids in rheumatic diseases. Ann NY Acad Sci. 2014;1318:55\u201364.","journal-title":"Ann NY Acad Sci"},{"key":"1515_CR6","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1089\/gtmb.2015.0227","volume":"20","author":"RH Mohamed","year":"2016","unstructured":"Mohamed RH, Mohamed RH, El-Shahawy EE. Relationship between RANK and RANKL gene polymorphisms with osteoporosis in rheumatoid arthritis patients. Genet Test Mol Biomarkers. 2016;20:249\u201354.","journal-title":"Genet Test Mol Biomarkers"},{"key":"1515_CR7","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1136\/ard.2006.068247","volume":"67","author":"SW Syversen","year":"2008","unstructured":"Syversen SW, Gaarder PI, Goll GL, \u00d8deg\u00e5rd S, Haavardsholm EA, Mowinckel P, et al. High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study. Ann Rheum Dis. 2008;67:212\u20137.","journal-title":"Ann Rheum Dis"},{"key":"1515_CR8","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jcdr.2012.09.003","volume":"4","author":"B Arnab","year":"2013","unstructured":"Arnab B, Biswadip G, Arindam P, Shyamash M, Anirban G, Rajan P. Anti-CCP antibody in patients with established rheumatoid arthritis: does it predict adverse cardiovascular profile? J Cardiovasc Dis Res. 2013;4:102\u20136.","journal-title":"J Cardiovasc Dis Res"},{"key":"1515_CR9","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham 3rd CO, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569\u201381.","journal-title":"Arthritis Rheum"},{"key":"1515_CR10","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1136\/annrheumdis-2014-205428","volume":"74","author":"C Hecht","year":"2015","unstructured":"Hecht C, Englbrecht M, Rech J, Schmidt S, Araujo E, Engelke K, et al. Additive effect of anti-citrullinated protein antibodies and rheumatoid factor on bone erosions in patients with RA. Ann Rheum Dis. 2015;74:2151\u20136.","journal-title":"Ann Rheum Dis"},{"key":"1515_CR11","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s00198-004-1780-5","volume":"16","author":"JA Kanis","year":"2005","unstructured":"Kanis JA, Borgstrom F, De Laet C, Johansson H, Johnell O, Jonsson B, et al. Assessment of fracture risk. Osteoporos Int. 2005;16:581\u20139.","journal-title":"Osteoporos Int"},{"key":"1515_CR12","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s00198-005-0027-4","volume":"17","author":"ES Siris","year":"2006","unstructured":"Siris ES, Brenneman SK, Barrett-Connor E, Miller PD, Sajjan S, Berger ML, et al. The effect of age and bone mineral density on the absolute, excess, and relative risk of fracture in postmenopausal women aged 50\u201399: results from the national osteoporosis risk assessment (NORA). Osteoporos Int. 2006;17:565\u201374.","journal-title":"Osteoporos Int"},{"key":"1515_CR13","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1080\/03009740801998812","volume":"37","author":"H Guler","year":"2008","unstructured":"Guler H, Turhanoglu AD, Ozer B, Ozer C, Balci A. The relationship between anti-cyclic citrullinated peptide and bone mineral density and radiographic damage in patients with rheumatoid arthritis. Scand J Rheumatol. 2008;37:337\u201342.","journal-title":"Scand J Rheumatol"},{"key":"1515_CR14","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315\u201324.","journal-title":"Arthritis Rheum"},{"key":"1515_CR15","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00223-017-0253-8","volume":"101","author":"G Orsolini","year":"2017","unstructured":"Orsolini G, Caimmi C, Viapiana O, Idolazzi L, Fracassi E, Gatti D, et al. Titer-dependent effect of anti-citrullinated protein antibodies on systemic bone mass in rheumatoid arthritis patients. Calcif Tissue Int. 2017;101:17\u201323.","journal-title":"Calcif Tissue Int"},{"key":"1515_CR16","doi-asserted-by":"crossref","unstructured":"Wysham KD, Shoback DM, Imboden Jr JB, Katz PP. Association of high anti-cyclic citrullinated peptide seropositivity and lean mass index with low bone mineral density in rheumatoid arthritis. Arthritis Care Res (Hoboken); 2017. \n                    https:\/\/doi.org\/10.1002\/acr.23440\n                    \n                  .","DOI":"10.1002\/acr.23440"},{"key":"1515_CR17","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s00296-017-3674-9","volume":"37","author":"I Llorente","year":"2017","unstructured":"Llorente I, Merino L, Ortiz AM, Escolano E, Gonz\u00e1lez-Ortega S, Garc\u00eda-Vicu\u00f1a R, et al. Anti-citrullinated protein antibodies are associated with decreased bone mineral density: baseline data from a register of early arthritis patients. Rheumatol Int. 2017;37:799\u2013806.","journal-title":"Rheumatol Int"},{"issue":"1","key":"1515_CR18","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/s13075-016-1116-9","volume":"18","author":"S Bugatti","year":"2016","unstructured":"Bugatti S, Bogliolo L, Vitolo B, Manzo A, Montecucco C, Caporali R. Anti-citrullinated protein antibodies and high levels of rheumatoid factor are associated with systemic bone loss in patients with early untreated rheumatoid arthritis. Arthritis Res Ther. 2016;18(1):226.","journal-title":"Arthritis Res Ther"},{"key":"1515_CR19","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1001\/archderm.1996.03890260086013","volume":"132","author":"IM Zonneveld","year":"1996","unstructured":"Zonneveld IM, Bakker WK, Dijkstra PF, Bos JD, van Soesbergen RM, Dinant HJ. Methotrexate osteopathy in long-term, low-dose methotrexate treatment for psoriasis and rheumatoid arthritis. Arch Dermatol. 1996;132:184\u20137.","journal-title":"Arch Dermatol"},{"key":"1515_CR20","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1136\/ard.2005.038851","volume":"65","author":"HA Chen","year":"2006","unstructured":"Chen HA. The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis. Ann Rheum Dis. 2006;65:35\u20139.","journal-title":"Ann Rheum Dis"},{"key":"1515_CR21","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jbspin.2014.10.015","volume":"82","author":"K Briot","year":"2015","unstructured":"Briot K, Rouanet S, Schaeverbeke T, Etchepare F, Gaudin P, Perdriger A, et al. The effect of tocilizumab on bone mineral density, serum levels of Dickkopf-1 and bone remodeling markers in patients with rheumatoid arthritis. Joint Bone Spine. 2015;82:109\u201315.","journal-title":"Joint Bone Spine"},{"key":"1515_CR22","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1136\/ard.2007.086348","volume":"68","author":"M Guler-Yuksel","year":"2009","unstructured":"Guler-Yuksel M, Allaart CF, Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, van Groenendael JH, Mall\u00e9e C, et al. Changes in hand and generalised bone mineral density in patients with recent-onset rheumatoid arthritis. Ann Rheum Dis. 2009;68:330\u20136.","journal-title":"Ann Rheum Dis"},{"key":"1515_CR23","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1172\/JCI60975","volume":"122","author":"U Harre","year":"2012","unstructured":"Harre U, Georgess D, Bang H, Bozec A, Axmann R, Ossipova E, et al. Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Invest. 2012;122:1791\u2013802.","journal-title":"J Clin Invest"},{"key":"1515_CR24","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1136\/annrheumdis-2015-208093","volume":"75","author":"A Krishnamurthy","year":"2016","unstructured":"Krishnamurthy A, Joshua V, Haj Hensvold A, Jin T, Sun M, Vivar N, et al. Identification of a novel chemokine-dependent molecular mechanism underlying rheumatoid arthritis-associated autoantibody-mediated bone loss. Ann Rheum Dis. 2016;75:721\u20139.","journal-title":"Ann Rheum Dis"},{"key":"1515_CR25","doi-asserted-by":"publisher","first-page":"3104","DOI":"10.1002\/art.22117","volume":"54","author":"TP Staa van","year":"2006","unstructured":"van Staa TP, Geusens P, Bijlsma JW, Leufkens HG, Cooper C. Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54:3104\u201312.","journal-title":"Arthritis Rheum"},{"key":"1515_CR26","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1093\/rheumatology\/ket353","volume":"53","author":"A Mohammad","year":"2013","unstructured":"Mohammad A, Lohan D, Bergin D, Mooney S, Newell J, O\u2019Donnell M, et al. The prevalence of vertebral fracture on vertebral fracture assessment imaging in a large cohort of patients with rheumatoid arthritis. Rheumatology (Oxford). 2013;53:821\u20137.","journal-title":"Rheumatology (Oxford)"},{"key":"1515_CR27","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.3899\/jrheum.150325","volume":"42","author":"Y Yamamoto","year":"2015","unstructured":"Yamamoto Y, Turkiewicz A, Wingstrand H, Englund M. Fragility fractures in patients with rheumatoid arthritis and osteoarthritis compared with the general population. J Rheumatol. 2015;42:2055\u20138.","journal-title":"J Rheumatol"},{"key":"1515_CR28","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1136\/annrheumdis-2015-208958","volume":"75","author":"C Klop","year":"2016","unstructured":"Klop C, de Vries F, Bijlsma JWJ, Leufkens HGM, Welsing PMJ. Predicting the 10-year risk of hip and major osteoporotic fracture in rheumatoid arthritis and in the general population: an independent validation and update of UK FRAX without bone mineral density. Ann Rheum Dis. 2016;75:2095\u2013100.","journal-title":"Ann Rheum Dis"},{"key":"1515_CR29","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.3346\/jkms.2014.29.8.1082","volume":"29","author":"JH Lee","year":"2014","unstructured":"Lee JH, Suh YS, Koh JH, Jung SM, Lee JJ, Kwok SK, et al. The risk of osteoporotic fractures according to the FRAX model in Korean patients with rheumatoid arthritis. J Korean Med Sci. 2014;29:1082\u20139.","journal-title":"J Korean Med Sci"},{"key":"1515_CR30","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jocd.2013.03.014","volume":"17","author":"T Friis-Holmberg","year":"2014","unstructured":"Friis-Holmberg T, Rubin KH, Brixen K, Tolstrup JS, Bech M. Fracture risk prediction using phalangeal bone mineral density or FRAX\u00ae?\u2014A Danish cohort study on men and women. J Clin Densitom. 2014;17:7\u201315.","journal-title":"J Clin Densitom"},{"key":"1515_CR31","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s00198-010-1524-7","volume":"22","author":"JA Kanis","year":"2011","unstructured":"Kanis JA, Johansson H, Oden A, McCloskey EV. Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int. 2011;22:809\u201316.","journal-title":"Osteoporos Int"},{"key":"1515_CR32","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1136\/annrheumdis-2014-205698","volume":"75","author":"A Kastbom","year":"2016","unstructured":"Kastbom A, Forslind K, Ernestam S, Geborek P, Karlsson JA, Petersson IF, et al. Changes in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: results from the SWEFOT trial. Ann Rheum Dis. 2016;75:356\u201361.","journal-title":"Ann Rheum Dis"},{"key":"1515_CR33","first-page":"1067","volume":"26","author":"M Cuchacovich","year":"2008","unstructured":"Cuchacovich M, Catalan D, Wainstein E, Gatica H, Soto L, Aravena O, et al. Basal anti-cyclic citrullinated peptide (anti-CCP) antibody levels and a decrease in anti-CCP titres are associated with clinical response to adalimumab in rheumatoid arthritis. Clin Exp Rheumatol. 2008;26:1067\u201373.","journal-title":"Clin Exp Rheumatol"},{"key":"1515_CR34","first-page":"424","volume":"34","author":"F Iannone","year":"2016","unstructured":"Iannone F, Tampoia M, Giannini M, Lopalco G, Cantarini L, Villalta CD, et al. Changes in anti-cyclic citrullinated peptide antibodies and rheumatoid factor isotypes serum levels in patients with rheumatoid arthritis following treatment with different biological drugs. Clin Exp Rheumatol. 2016;34:424\u20139.","journal-title":"Clin Exp Rheumatol"},{"key":"1515_CR35","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/nrrheum.2011.76","volume":"7","author":"WJ Venrooij van","year":"2011","unstructured":"van Venrooij WJ, van Beers JJBC, Pruijn GJM. Anti-CCP antibodies: the past, the present and the future. Nat Rev Rheumatol. 2011;7:391\u20138.","journal-title":"Nat Rev Rheumatol"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-018-1515-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,29]],"date-time":"2019-01-29T19:59:31Z","timestamp":1548791971000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-018-1515-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,30]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1515"],"URL":"https:\/\/doi.org\/10.1186\/s13075-018-1515-1","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,30]]},"assertion":[{"value":"25 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Regional Ethical Review Board of CGMHK (104-3530B), and the patients gave written consent according to the Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"16"}}